Eric Low

[British Journal of Haematology @BrJHaem]

Recommendations on diagnosis and initial treatment of patients with transplant-eligible high-risk multiple myeloma by the British Society of Haematology/UK Myeloma Society
https://t.co/pRIcPEEUwr
@MyMKaiser
@DrSStern
@JennerMatthew
@UKMyelomaSoc

[Simon Stern @DrSStern]

Delighted that the @BritSocHaem @UKMyelomaSoc Good Practice Paper on the treatment of high risk transplant-eligible myeloma is now published. Many thanks to @MyMKaiser for his great input. #mmsm
British Journal of Haematology | Wiley Online Library https://t.co/k3xBCOhthv

[Consilium Scientific @consiliumsci]

Legendary @f2harrell is back at Consilium next week! Sign up here for the talk https://t.co/pxT3HfLoTL @PotardDechaine @EricLow71 @DrAmandaAdler @david_colquhoun @bogdienache @rarediseaseuk @ResurgeQuality @Richard_D_Riley @vandy_biostat @BabakWork

[Consilium Scientific @consiliumsci]

Great job @EMA_News @HAImedicines @TranspariMED @Meds_Alliance! Learn more here https://t.co/L0K4EkHO2T
@nogracias_eu @RevuePrescrire @ISRCTN @METRICStanford @Marguerite_OR @Jhickmana @EricLow71 @GustavNilsonne @NDevito1

[awechalekar @awechalekar]

An exciting clinical research fellow in haematology post now open at UK National Amyloidosis Centre and UCLH amyloidosis/MGCS trials clinic - see #nhsjobs - 2-3 yrs with opportunities to do a PhD at UCL. @OSociety @BritSocHaem @EHA_Hematology @ASH_hematology @LinkedIn

[Hira Mian @HiraSMian]

Everyone must come! Great science, great city, great food and you get to hang out with cool #mmsm Canadian colleague hosts :) we look forward to welcoming everyone.

[Martin Kaiser @MyMKaiser]

Last chance for the #myeloma MRI quiz...

[Consilium Scientific @consiliumsci]

Join us for a special event to depict HTA methodology and celebrate the legacy of Dr.Eli Gajraj. Sign up here: https://t.co/2f5W0wzmiL @FrancoisMaignen @JacolineBouvy @SirAndrewDillon @dollendorf @OortwijnW @decide_health @NICESciAdvice @EUnetHTA @EricLow71 @pilarpinilladom

[Martin Kaiser @MyMKaiser]

Many thanks, very kind. Deeply feel we should discuss the value of extended upfront risk molecular diagnostic tests more in #myeloma , not only price. We might find that they will help allocate other rare resources like imaging or MRD tests throughout treatment phases better.

[Jack Scannell @JackScannell13]

Don't read? Well, here is the podcast: https://t.co/5mc5VBC45l

[Consilium Scientific @consiliumsci]

Join Consilium on June 16th for a talk from our brilliant AdBoard member Jack Scannell. Sign up here:
https://t.co/PLHMMGDBH9 @Jhickmana @rkessler05 @RevuePrescrire @david_colquhoun @LSEHealthPolicy @HealthSenseUK @TranspariMED @HAImedicines @EricLow71 @Anticancerfund

[Jack Scannell @JackScannell13]

$50 billion a year is spent on failed cancer drug development by the pharma industry. Our new paper is a case study on what goes wrong. @consiliumsci @Jhickmana
https://t.co/jdkIdFpZae

[Eric Low @EricLow71]

@JackScannell13 @consiliumsci @Jhickmana Super insightful paper and one that all policy-makers and advocates should read.

[Consilium Scientific @consiliumsci]

If you missed a brilliant talk by @DrDavidHealy at Consilium, watch here https://t.co/aar6sUrLeM @riotscience_wlv @UKRIO @uaem @Jhickmana @eturnermd1 @EricLow71 @NaudetFlorian @susan_bewley @pash22 @HealthSenseUK @pssd_awareness @cheesyredrocket @PatrickChance @PatientStormDoc

[Consilium Scientific @consiliumsci]

Join to learn the results of the Consilium’s @MyelomaEurope funded project on QoL in multiple myeloma trials @Care4Access @KateEMor_ @drkevinknopf @MyMKaiser @FrancoisMaignen @EricLow71 @MyelomaUK @patvocates @Jhickmana @peterbachmd @AaronGoodman33 @VincentRK @pash22 @IMFmyeloma

[Consilium Scientific @consiliumsci]

If you missed an excellent talk on multi-modal cancer screening tests by @paulpharoah last week, watch here https://t.co/OxdAZzmUdJ @ecancer @drkevinknopf @oncology_bg @EAEisenhauer @MyMKaiser @EricLow71 @EuropeanCancer @CRUK_Policy

[Consilium Scientific @consiliumsci]

If you missed an excellent live debate organised by @TranspariMED on how the UK trial transparency system can be implemented in other countries, watch here https://t.co/ZciLVwEo2w @cmarctaylor @Strech_Da @NDevito1 @HRA_Latest @matt_westmore @berlinnovation @EricLow71 @Jhickmana

[Martin Kaiser @MyMKaiser]

Will be very interesting to see how this will work in practice - a fantastic, extremely scalable technology. And of course hoping #myeloma patients may be included as well! @BioNTech_Group @NCRI_partners #MMsm

https://t.co/7MSAAqCCHX

[Eric Low @EricLow71]

@kennycairns @LeedsCTRU The Leeds CTRU are the bedrock behind all the best UK myeloma trials, and they don't get the credit, recognition and protection they deserve. It's great that they get the recognition they deserve in this paper.

[Eric Low @EricLow71]

@kennycairns @LeedsCTRU The Leeds CTRU is the bedrock of all the best UK trials. I suspect they don't get the credit, protection and funding they deserve. Seeing them get the recognition they deserve in this paper is great.